Ru Back Packer

Quotes delayed 20 minutes

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Free Preferred Stock Newsletter
Gain access to weekly reports with featured preferred stock screens, new preferred stock offerings, and more.

Slideshow Preferred Stock Offerings

By Ru Back Packer Staff, updated Thursday, February 1, 6:43 AM

Slide #85. Sunesis Pharmaceuticals, Inc. Preferred Stock Offering

Company: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)
Date announced: 10/18/2016
Preferred Stock Offering Details: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series C Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the offerings. Sunesis also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offering for clinical development of SNS-062, regulatory development of vosaroxin in Europe and other general corporate purposes.

Sunesis Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Co. has commercial rights to SNS-062, a selective non-covalently binding, reversible oral inhibitor of Bruton's tyrosine kinase; and commercial rights to several potential pre-clinical inhibitors of the target PDK1. Co. is also in a collaboration with Takeda Pharmaceutical Company Limited for the development of TAK-580, an oral pan-RAF inhibitor. Co.'s key program is QINPREZO™ (vosaroxin), its product candidate for the potential treatment of acute myeloid leukemia. Vosaroxin is an anticancer quinolone derivative.
Open the SNSS Page at Ru Back Packer »

Name: Sunesis Pharmaceuticals Inc
Sector: Drugs & Pharmaceuticals
Number of ETFs Holding SNSS: 2 (see which ones)
Total Market Value Held by ETFs: $336,008
Total Market Capitalization: $157,000,000
% of Market Cap. Held by ETFs: 0.21%

Open the SNSS Page at Ru Back Packer (in a new window) »

Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference

The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500

Preferred Stock Offerings - Slide 85 of 414 | | Copyright © 2011 - 2018, All Rights Reserved